Condition 1: Hemodialysis patients. Condition 2: Hemodialysis patients. Condition 3: Hemodialysis patients. Renal failure Renal failure Renal failure
Conditions
Interventions
Treatment - Drugs
Placebo
Intervention 1: Intervention group: N-acetylcysteine with the trade name Fluimucil, as 600 milligram tablet, made by Swiss Zambon Svizzerasa company, given twice daily (every 12 hours), per oral for 6
Intervention group: N-acetylcysteine with the trade name Fluimucil, as 600 milligram tablet, made by Swiss Zambon Svizzerasa company, given twice daily (every 12 hours), per oral for 6 weeks.
Control group: Placebo as 600 milligram tablet, twice daily, every 12 hours, per oral for 6 weeks, made from micro-crystalline cellulose, lactose, corn starch, talk (2% of total tablet weight) which m
Sponsors
Vice Chancellor for Development, Research and Technology of Ahvaz Jondishapour University of Medical
Eligibility
Sex/Gender
All
Age
16 Years to 100 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1) all of the chronic hemodialysis patients due to end stage renal disease more than 18 years old and at least three months has been past from starting of hemodialysis. Exclusion criteria: 1) Every acute disease leads to hospitalization from one month before trial. 2) Allergy to N-acetylcysteine. 3) Hepatic cirrhosis 4) Using Vitamin E or C or every known antioxidant from two weeks before intervention. 5) congestive heart failure or ejection fraction less than 35%. 6) Non using of N-acetylcysteine or placebo more than 20% of total drug.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Malondialdehyde. Timepoint: Before intervention and 6 weeks after intervention. Method of measurement: With malondialdehyde kit spectrophotometry method in mmol/lit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Itching. Timepoint: Before intervention and 6 weeks after intervention. Method of measurement: Visual. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Javaherforoushzadeh
Ahvaz Jondishapour University of Medical Sciences
Outcome results
None listed